CAMMA-1
Phase 1B Clinical Trial Studying the Safety, Activity, and Effectiveness of Cevostamab in Treating People with Relapsed or Refractory Multiple Myeloma
More Information
- Trial Status
- Not currently accepting
- Trial Phase
- Phase 1
- Enrollment
- 170 patients (estimated)
- Sponsors
- Genentech
- Collaborators
- Hoffmann-La Roche
- Tags
- Bispecific Antibody, CD3, FCRH5
- Trial Type
- Treatment
- Last Update
- 2 weeks ago
- SparkCures ID
- 1175
- NCT Identifier
- NCT04910568
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.